Hôpital Archet 2

The gastroenterology team at Hôpital Archet 2 is conducting research aimed at reducing postoperative recurrence of Crohn's disease by testing a new therapeutic agent and refining endoscopic assessment methods.

• Evaluation of the novel biologic EXL01 for disease control
• Use of endoscopic modified Rutgeerts scores to monitor treatment response
• Strategies to prevent post‑surgical disease flare‑ups

With a team of 10 investigators, the site is advancing personalized care for patients with inflammatory bowel disease in Nice, France.

In the oncology division, researchers are exploring ways to improve outcomes for newly diagnosed metastatic Ewing Sarcoma by integrating targeted agents, maintenance chemotherapy, and optimized radiotherapy protocols.

• Adding regorafenib to standard VDC/IE chemotherapy
• Assessing maintenance regimens of vinorelbine and cyclophosphamide
• Investigating radiotherapy dose escalation for inoperable tumors
• Comparing post‑operative radiotherapy dose levels for optimal control

The collaborative effort of 10 investigators at this French research centre seeks to set new standards for sarcoma treatment across Europe.